Detailed Materials and Methods having information about study design, experimental strategy, and statistical methods, including single-marker analyses, multiple imputation, and multiple-marker analyses, are available in the online-only Supplement.
A therosclerotic cardiovascular diseases (ASCVD) are a leading cause of morbidity and death globally. 1 A more accurate assessment of ASCVD risk could lead to earlier treatments to delay disease onset and prevent the occurrence of clinical events and death. Efforts to improve the detection of ASCVD include the use of risk assessment algorithms that take into consideration age, sex, and several established clinical risk factors. 2 Several studies have attempted to identify plasma protein biomarkers of ASCVD to improve the detection of individuals at increased risk for ASCVD. 3, 4 The extent to which plasma protein biomarkers improve the prediction of risk for ASCVD beyond established risk factors remains controversial. 5 As part of the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) Initiative, which seeks to discover biomarkers of ASCVD and its major risk factors, we sought to identify plasma protein biomarkers of new-onset myocardial infarction (MI) and ASCVD in participants from the Framingham Heart Study. Identification of novel biomarkers that individually or in aggregate predict risk of ASCVD could provide insight into the biology of the disease and could aid in developing targeted prevention strategies during the preclinical phase of ASCVD, when intervention may be more likely to alter disease progression.
Results

Isobaric Tag for Relative and Absolute Quantification Discovery
Baseline characteristics of 135 pairs of MI cases and controls with protein levels are summarized in Table 1 . Systolic blood pressure, total cholesterol, and body mass index were higher, and high-density lipoprotein-cholesterol was lower in cases than in controls. Diabetes mellitus and hypertension treatment were more common in cases than in controls. The median follow-up time (from the baseline examination to event occurrence) was 2.34 years with lower and upper quartiles 1.11 years and 4.06 years. In total, 861 proteins were measured by isobaric tag for relative and absolute quantification (iTRAQ).
Single-Marker Analysis
Among the iTRAQ measured proteins, 34 had no known protein annotation (ie, classified as unknown) and, for 39 proteins, multiple isoforms were identified; this left 753 unique known markers, among which results for 168 markers were available in fewer than 40 pairs of individuals. We used markers with data available on ≥40 case-control pairs because for covariate adjusted analysis we required that ≥5 to 10 events per variable in a model were present. 6 Of 587 unique markers tested for association with MI, none had a P value that attained overall significance after Bonferroni correction (0.05/587; P<8.5E-05). The top 10 iTRAQ proteins associated with MI ( Table I in the online-only Data Supplement. Most, if not all, of the unidentified proteins are thought to be antibody fragments generated from the sample preparation workflow and not related to endogenous biomarkers. Different isoforms could be from post-translational modification or a cleaved or truncated version of the same marker. In statistical analysis, we prioritized isoforms with complete data if possible. However because of funding and laboratory restrictions and limited nonrenewable plasma samples, we did not attempt to further identify the exact nature of these unidentified products or isoforms.
Multiple-Marker Analysis
To identify a multiple-marker protein panel from iTRAQ that was significantly associated with MI, we performed analyses for 544 proteins (measured in ≥60% samples) using stepwise selection within bins as detailed in the Materials and Methods section. The number of times that a marker was retained in the final model varied from 1 to 259 (out of 260 runs). Using multiple imputation-stepwise selection based on 26 protein markers that were selected >50% of time, we identified a multiple-marker panel of 7 proteins associated with MI status. The multiple-marker panel included cyclophilin A, CD5 antigen-like, cell-surface glycoprotein mucin cell surface associated protein 18 (MUC18) collagen α-1 (XVIII), salivary α-amylase 1, C-reactive protein, and multimerin-2 ( Table 3 ). The C-statistic from the model with clinical covariates only was 0.71. The median C-statistic for the multiplemarker model (based on each of 20 imputed data sets) was 0.84 (limits across imputations, 0.81-0.87). The combination Table 2 This table shows markers with P<0.01 in either conditional logistic regression or paired t test. For each biomarker, data were rank normalized and have mean 0, SD 1. Differences, standard errors (SE), and odds ratios are in unit of 1 SD. The conditional logistic regression (CLR) model was adjusted for age, sex, current smoking status, statin use, systolic blood pressure, hypertension treatment status, total cholesterol, high-density lipoprotein-cholesterol, diabetes mellitus status, and body mass index. Results are sorted by CLR values. All analyses are based on available data. CI indicates confidence intervals; and iTRAQ, isobaric tag for relative and absolute quantification. In single-marker analysis ( Table 2) , glycoprotein 5 was the strongest predictor of MI. This maker was among the top 26 markers that were selected >50% of the time, but it narrowly missed stepwise selection (P=0.056) adjusting for variables chosen in the final model.
. Top Protein Biomarkers of Myocardial Infarction: Results of Single-Marker Analyses From iTRAQ Mass Spectrometry
Multiple Reaction Monitoring and Depletion Multiple Reaction Monitoring
Single-Marker Analysis
The top proteins in single-or multiple-marker analysis from iTRAQ were assayed on 336 pairs of ASCVD cases and controls. Multiple reaction monitoring (MRM) or depletion MRM was not attempted on any markers identified from iTRAQ discovery if their plasma concentrations were below the detection limits of MRM technology (see Methods section in the online-only Data Supplement). A total of 32 protein markers were measured by MRM and 27 by depletion MRM. In individual marker analyses, the top MRM markers associated with ASCVD were α-1-acid glycoprotein 1, C-reactive protein, ceruloplasmin, serum amyloid A-1 protein, gelsolin, tetranectin, hemopexin, paraoxonase 1, protein Z-dependent protease inhibitor, and leucine-rich α-2-glycoprotein (P<0.05 in the risk factor-adjusted conditional logistic regression model; Table 4 ). The top proteins associated with ASCVD among those measured by depletion MRM included protein Z-dependent protease inhibitor and neural cell adhesion molecule 1 ( Table 4 ). The remaining markers we measured using MRM and depletion MRM are available in Table II in the online-only Data Supplement.
Multiple-Marker Analysis
In risk factor-adjusted multiple biomarker analysis from MRM and depletion MRM, α- Table 5 ). The C-statistic of the model with clinical covariates only was 0.69; with the addition of the panel of 4 protein biomarkers, the C-statistic rose to 0.74. The likelihood ratio test showed that these proteins were associated with ASCVD (P<0.0001). Among cases, the gain in predicted probability of being a case from the clinical model to multiple-marker model had a mean of 0.032 (standard error, 0.007).
We repeated multiple-marker analysis on the 135 MI casecontrol pairs included in the MRM and depletion MRM analysis. Protein Z-dependent protease inhibitor (OR per 1 SD=1.7, 95% CI [1.16, 2.50]), C-reactive protein (OR, 1.51; 95% CI [1.03, 2.23]), and CD5 antigen-like (OR, 0.7; 95% CI [0.50, 0.98]) in combination predicted the new onset of MI. The addition of these 3 markers to the clinical risk factors increased the C-statistic from 0.72 to 0.76. The likelihood ratio test showed these protein biomarkers to be jointly associated with ASCVD (P<0.0001). Among cases, the mean gain in predicted probability of being a case from the clinical model to multiple-marker model was 0.068 (standard error, 0.015). We acknowledge that some markers contribute to only either MI or only ASCVD, and some markers contribute to both outcomes in multiple-marker analysis but with different effect sizes. This could be because of the following reasons. One is that the proteins might play different roles in MI than in the other ASCVD diseases (eg, acute thrombotic events versus chronic atherosclerotic disease). The second reason is that the 2 analyses were based in part on different samples. The analysis for MI was based on 135 pairs of MI cases and controls; ASCVD analysis was based on 336 pairs of ASCVD cases and controls (including the MI pairs). The third reason is that the set of candidate markers is not identical for different outcomes. In joint modeling, the effect size and direction of a specific marker is affected by other markers in the same model.
Discussion
Through discovery and targeted proteomic studies, we identified single protein biomarkers that were associated with risk of MI or ASCVD. We also identified panels of proteins that in aggregate improved MI and ASCVD risk prediction above and beyond established risk factors. We included up to 587 protein biomarkers assayed by iTRAQ discovery mass spectrometry of MI cases and controls. After adjusting for established risk factors, the top iTRAQ-derived protein biomarkers of MI in single-marker analyses were glycoprotein 5, CD5 antigen-like, myoglobin, protein kinase C inhibitor protein 1, C-reactive protein, cyclophillin A, contactin-1, and albumin (P=0.007). Cyclophilin A, CD5 antigen-like, cell-surface glycoprotein MUC18, collagen α-1(XVIII) chain, salivary α-amylase 1, C-reactive protein, and multimerin-2 emerged as a multiple-marker protein panel for MI (P<0.0001). This panel of 7 proteins improved MI risk prediction compared with clinical risk factors only, with a model C-statistic of 0.84 (versus 0.71 for the clinical risk factor only model, P<0.0001). Additional studies are warranted to determine whether the multiple markers we identified can be replicated and, if so, whether adding protein panels to models based on conventional risk factors demonstrates clinical use for the multiple-marker panel.
We then targeted 32 and 27 proteins for measurement by MRM and depletion MRM mass spectrometry, respectively. Alpha-1-acid glycoprotein, C-reactive protein, ceruloplasmin, serum amyloid A-1 protein, gelsolin, tetranectin, hemopexin, paraoxonase 1, protein Z-dependent protease inhibitor, and leucine-rich α-2-glycoprotein were the top MRM markers of ASCVD in single-marker analyses (at P<0.05). The top proteins associated with ASCVD among those measured by depletion MRM were protein Z-dependent protease inhibitor and neural cell adhesion molecule 1 (at P<0.05). In multiple-marker analysis of the combined MRM platforms, α-1-acid glycoprotein, paraoxonase 1, tetranectin, and CD5 antigen-like in combination predicted incident ASCVD (P<0.0001) and increased the C-statistic from the model with clinical covariates (0.69-0.73; P<0.0001). The panel of 3 MRM markers that predicted MI (which included CD5 antigen-like, C-reactive protein, and protein Z-dependent protease inhibitor) increases the C-statistic from 0.72 to 0.76 (P<0.0001).
Our proteomic work identified several novel biomarkers of MI and ASCVD; 9 of our markers were significant in a previous proteomic study of cardiovascular disease-related outcomes. 7 Prentice et al 7 used proteomic screening of plasma from cases and controls in the Women's Health Initiative in an effort to identify proteomic biomarkers of coronary heart disease and stroke. The main difference between their proteomics study and ours is that they pooled plasma samples from cases (and controls), precluding individual participant level analyses or complete adjustment for multiple ASCVD risk factors. They identified 37 proteins that were nominally associated Results are all from stepwise selection in conditional logistic regression models, adjusting for age, sex, current smoking status, statin use, systolic blood pressure, hypertension treatment status, total cholesterol, high-density lipoprotein-cholesterol, diabetes mellitus status and body mass index. Candidate markers include all 59 proteins measured by MRM and depletion MRM. P value of 0.05 was used as both enter and stay criteria. For each biomarker, data were rank normalized and have mean 0, SD 1. Odds ratios are in unit of 1 SD. ASCVD indicates atherosclerotic cardiovascular disease; CI, confidence intervals; MI, myocardial infarction; and MRM, multiple reaction monitoring.
with coronary heart disease and 47 proteins associated with stroke. 7 In their study, CD5 antigen-like, cyclophilin A, monocyte differentiation antigen CD14, multimerin-2, sulfhydryl oxidase 1, extracellular superoxide dismutase [Cu-Zn], apolipoprotein A-II, granulin, and insulin-like growth factor-binding protein 5 all had nominal P values <0.05.
Our MI prediction model included novel proteins for which associations with ASCVD have not previously been reported at the population level. Such markers include: collagen α-1(XVIII) chain, cyclophilin A, CD5 antigen-like, and salivary α-amylase 1. Cyclophilin A (coded for by the gene PPIA) was protective in our study (OR per 1 SD=0.34, 95% CI [0.18, 0.63]; P=0.0008 in multiple-marker analysis). It is a ubiquitous, intracellular protein that plays a role in protein folding and trafficking. It is secreted by cells in response to inflammatory stimuli, especially oxidative stress. 8 Nigro et al 9 found that atherosclerosis was greater in apolipoprotein E (APOE) knockout mice versus double knockouts for APOE and PPIA. Human studies have shown a positive association between cylclophilin A and atherosclerosis 10 and congestive heart failure. 11 In a cross-sectional study, 12 cyclophilin A levels were associated with coronary atherosclerosis. To our knowledge, there has been no previous prospective study of the association of circulating cyclophilin A with the incidence of MI.
CD5 antigen-like (CD5L) is a cell-surface ligand on activated lymphocytes, 13 and its function in atherogenesis largely remains unknown. 14 Collagen α-1 (XVIII) chain (COL18A1) is a basement protein and its C-terminus encodes for endostatin, a 20-kDa proteolytic fragment that inhibits angiogenesis and atherosclerosis. 15 When atherosclerosis prone APOE knockout mice were bred with COL18A1 knockout mice, there was extensive intimal neovascularization in the double knockouts. 16 This may suggest a mechanistic relation between collagen α-1 (XVIII) and atherosclerosis, because plaque neovascularization is thought to promote atherosclerosis. Salivary α-amylase 1 cleaves starch glycosidic linkages to produce smaller saccharides; α-amylase 1 is higher in populations that have evolved under high-starch diets and may modulate glycemic response after glucose intake. 17 Among the proteins identified by MRM as being associated with ASCVD, α-1-acid glycoprotein is an acute phase protein that is secreted by the liver and measurable in plasma. It is an abundant plasma protein that increases in response to infection, inflammation, tissue injury, or cancer. 18, 19 Its biological function remains unknown. Paraoxonase is a component of high-density lipoprotein-cholesterol and protects low-density lipoprotein from oxidative modification, and thus delays the progression of atherosclerosis. Lower circulating levels of paraoxonase 1 have been reported to be associated with risk of MI [20] [21] [22] [23] [24] and, in Framingham, we detected an association with ASCVD with similar directionality (OR per 1 SD=0.79, 95% CI [0.64, 0.98]; P=0.031) and an association with MI (level in cases lower than that in controls, 0.24±0.09 SD; P=0.015). Tetranectin is an adhesion molecule found on endothelial cells and platelets. 25 Tetranectin is released by platelets and binds to the plasminogen kringle 4 domain; it enhances plasminogen activation and inhibits the proliferation of endothelial cells. 26 Population studies have shown that decreased plasma tetranectin levels are associated with coronary artery disease. 27 Our study shows similar results, albeit using a prospective study design; higher tetranectin levels were inversely associated with risk of ASCVD (OR, 0.76; 95% CI [0.61, 0.95]; P=0.017).
Our study has several limitations. Despite the overlap of several of our ASCVD biomarkers with those reported in the literature (eg, C-reactive protein, α-1-acid glycoprotein 1, paraoxonase 1), many of our protein biomarkers are novel and our results require independent validation. Additionally, there is bias toward more abundant proteins via the proteomics approach, and a tradeoff exists between how many proteins can be identified and how accurately they can be quantified. Random factors play a role in our multiple-marker analysis of iTRAQ data. Despite these limitations, our study has several strengths. This is one of few proteomic studies of incident MI in an observational study setting. Our proteomics platforms enabled us to individually compare plasma samples of cases and controls and perform multiple-marker analyses. Additionally, we discovered single protein biomarkers and protein multiple markers, and evaluated their performance in prediction of MI and ASCVD.
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